A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Trial number:
NCT04567615
Trial phase:
2
Study type:
Immunotherapy, Targeted therapy
Overall status:
Recruiting

Study start date

February, 2021

Scientific title

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

Summary

The purpose of this study is to evaluate the effectiveness and safety of relatlimab in combination with nivolumab in participants with advanced liver cancer who have never been treated with immuno-oncology therapy, after prior treatment with tyrosine kinase inhibitor therapy.

Key

Must have a diagnosis of hepatocellular carcinoma (HCC) based on histological confirmationMust have advanced/metastatic HCC Have to be immunotherapy treatment-naive in the advanced/metastatic setting Must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 measurable untreated lesion Child-Pugh score of 5 or 6 Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 for ECOG performance status scale

Key

Study design

Primary purpose: Treatment, Allocation: Randomized, Intervention model: Parallel Assignment, Masking: None (Open Label),

Conditions

Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult

Other study ID numbers

CA224-073; 2018-003151-38; U1111-1218-6499

Choose trial site (158)